期刊
AMERICAN JOURNAL OF SURGICAL PATHOLOGY
卷 46, 期 11, 页码 1467-1476出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/PAS.0000000000001944
关键词
PRAME; immunohistochemistry; qPCR; ovarian carcinomas; seminoma; synovial sarcoma; myxoid liposarcoma; mucosal melanoma; metastatic melanoma; dedifferentiated melanoma
资金
- NCI's intramural research program
Preferentially expressed antigen in melanoma (PRAME) is a useful marker in distinguishing malignant melanoma from its mimics. This study found that PRAME is variably expressed in different types of malignancies, but it is strongly expressed in nonmelanocytic poorly differentiated carcinomas and sarcomas. Although the use of PRAME as an immunohistochemical marker in diagnostic surgical pathology is limited, immunohistochemistry is reliable and cost-effective for detecting PRAME-positive malignancies for potential immunotherapy.
Preferentially expressed antigen in melanoma (PRAME) is considered a useful marker in the differential diagnosis between malignant melanoma and its melanocytic mimics. Recently PRAME expression was documented in nonmelanocytic tumors, but much of the data are based on mRNA studies. This investigation evaluated PRAME expression in the spectrum of normal tissues and >5800 human tumors using immunohistochemistry and EP461 monoclonal antibody. In normal tissues, PRAME was expressed in the testis and proliferative endometrium. In tumors, PRAME was variably expressed in malignancies of different lineages. Among epithelial tumors, >50% of PRAME-positive lesions were found among endometrial carcinomas (82%), uterine serous carcinomas (82%), uterine carcinosarcomas (60%), ovarian clear cell carcinomas (90%), ovarian serous carcinomas (63%), adenoid cystic carcinomas (81%), seminomas (78%), thymic carcinomas (75%), and basal cell carcinomas (62%). In mesenchymal and neuroectodermal malignancies, PRAME was frequently expressed in synovial sarcoma (71%), myxoid liposarcoma (76%), neuroblastoma (61%) and metastatic melanoma (87%). Also, PRAME was consistently expressed in 4 melanomas that lacked all melanoma markers including S100 protein and SOX10 but harbored typical for melanoma BRAF or NRAS driver mutations. However, strong and diffuse PRAME immunoreactivity was seen in many types of nonmelanocytic poorly differentiated carcinomas and sarcomas. Based on this study, PRAME is a relatively unspecific immunohistochemical marker, which limits its use in diagnostic surgical pathology. However, immunohistochemistry is a reliable and unexpensive method useful in detecting PRAME-positive malignancies for potential immunotherapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据